Human Anti-EPHA2 Recombinant Antibody (clone G5) (CAT#: HPAB-0164CQ)

Figure 1 PC3 cells were labeled with either human α-EphA2 mAb (G5; panels A and B) Or R347 isotype control (panel C)

Cell surface attached antibodies were then allowed to Internalize by incubating the cells undergrowth conditions for either zero (non-internalized: panels A and C) or 60 minutes (internalized: panel B). All cells were then fixed (4% Paraformaldehyde), permeablized (0.5% Triton X-100), and stained with AlexaFuor 488-Ab Prior to addition of antifade mounting media and flourescent microscopy examination.

Figure 2 Comparison of internalization of several different anti-EphA2 antibodies.

Internalization of the anti EphA2 antibodies B233, B208, EA2, G5, 3F2, 1C1, C2, 3B2 is compared to controls in the following cell lines: PC3, SK Mel-28, HuVec, MCF 10A, and CT26.

Figure 3 In vitro growth inhibition of A498 cells, PC-3 cells, and MDA-MB-468 cells by the anti-EphA2 anti body G5 and EA5 linked to MMAF with the vc linker.

Concentrations tested ranged from 0.001 to 100 μg/ml. Results are summarized in three different panels of graphs.

Figure 4 In vivo comparison of the anti-EphA2 G5 antibody conjugated to MMAF with the vc linker as com pared to unconjugated G5, control IgG conjugated to MMAF, and control unconjugated IgG in the PC-3 human prostate cancer cell line.

Doses of antibodies were 20 μg and 200 μg.